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ABSTRACT
Objectives. Cardiovascular risk is increased in patients with systemic lupus erythematosus (SLE). Drugs used to treat
SLE can modify traditional cardiovascular risk factors. We examined the effect of selected drugs used in the
treatment of SLE on cardiovascular risk factors.
Methods. We compared systolic and diastolic blood pressure, serum lipid concentrations, glucose, homocysteine,
and urinary F2-isoprostane concentrations in 99 patients with lupus who were either current users or non-users of
systemic corticosteroids, antimalarials, non-steroidal anti-inﬂammatory drugs (NSAIDs), COX-2 selective NSAIDs,
azathioprine, and methotrexate. Multivariable adjustment was done with linear regression modeling using sex, age
and disease activity (SLEDAI) as controlling variables.
Results. Serum triglyceride concentrations were higher (135.1  61.4 vs. 95.3  47.5 mg/dL, adjusted P = 0.003) in
patients receiving corticosteroids. Homocysteine concentrations were marginally higher in patients receiving meth-
otrexate (adjusted P = 0.08). Current use of either NSAIDs or COX-2 inhibitors was not associated with increased
cardiovascular risk factors. Current hydroxychloroquine use was not associated with signiﬁcant alterations in lipid
proﬁles.
Conclusions. In a non-random sample of patients with SLE, current corticosteroid use was associated with increased
triglyceride concentrations, but other drugs had little effect on traditional cardiovascular risk factors.
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Introduction
P
atients with systemic lupus erythematosus
(SLE) have accelerated atherosclerosis and
increased cardiovascular morbidity and mortality
[1]. We have found that cardiovascular risk factors
such as triglyceride concentrations and the preva-
lence of hypertension were signiﬁcantly higher in
patients with SLE than controls [2]. Disease char-
acteristics, or drugs used to treat the disease, could
contribute to alterations in cardiovascular risk
factors. Drugs used to treat SLE such as corticos-
teroids, non-steroidal anti-inﬂammatory drugs
(NSAIDs) and COX-2 inhibitors can adversely
affect cardiovascular risk factors such as blood
pressure and lipid concentrations [3–5]. On the
other hand, hydroxychloroquine has been re-
ported to decrease total and LDL cholesterol and
triglyceride concentrations [6]. We examined the
hypothesis that current use of drugs used to treat
SLE affects cardiovascular risk factors.
Methods
This study enrolled 99 patients with SLE from the
Vanderbilt Lupus Cohort. This cohort had an
increased prevalence of coronary atherosclerosis
detected by electron-beam computed tomography
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detail elsewhere [2,7–9]. All subjects gave written
informed consent and the study was approved
by the Institutional Review Board of Vanderbilt
University Hospital. All patients met the 1997
American College of Rheumatology (ACR) classi-
ﬁcation criteria for SLE [10]. Patients with pre-
existing cardiovascular disease such as angina,
stroke or myocardial infarction and those receiving
lipid-loweringagentswereexcluded.Demographic
and disease characteristics and cardiovascular risk
factors including systolic and diastolic blood pres-
sure, serum HDL and LDL cholesterol, triglycer-
ides, glucose, serum homocysteine, and urine
F2-isoprostane concentrations, a measure of oxida-
tive stress [11], were measured.
Statistical Analysis
Cardiovascular risk factors were compared in
patients receiving or not receiving a drug of
interest (systemic corticosteroids, antimalarials,
NSAIDs, COX-2 inhibitors, azathioprine, and
methotrexate) using Mann-Whitney U tests.
Additional multivariable adjustment was per-
formed by linear regression using age, sex and
SLEDAI (Systemic Lupus Erythematosus Disease
Activity Index) [12] as controlling variables.
F2-isoprostane concentrations were logarithmic-
transformed for regression analysis. These analy-
ses were exploratory, therefore no adjustment for
multiple statistical comparisons were performed.
Statistical analysis was conducted using SPSS 15.0
for Windows (SPSS Inc., Chicago, USA). Descrip-
tive values are presented as mean  standard
deviation (SD). Statistical signiﬁcance was deter-
mined as P < 0.05.
Results
Descriptive data for the SLE population are shown
in Table 1. Cardiovascular risk factors in patients
receiving or not receiving the drugs of interest are
showninTables 2–7.AsshowninTable 2,corticos-
Table 1 Descriptive data for the study group (N = 99)
Factor Mean  SD
Age (years) 40.2  11.4
Sex (M/F)* 8/91
SLEDAI 4.3  4.0
SLICC 0.79  1.2
Systolic BP (mm Hg) 119.6  17.7
Diastolic BP (mm Hg) 73.8  13.8
HDL cholesterol (mg/dL) 48.0  14.8
LDL cholesterol (mg/dL) 105.4  37.3
Triglycerides (mg/dL) 119.4  59.4
Glucose (mg/dL) 87.1  27.0
Homocysteine (umol/L) 9.29  2.78
F2 Isoprostane (ng/mg Creatinine) 2.84  2.36
*Shown as frequency.
SD = standard deviation; SLEDAI = systemic lupus erythematosus disease
activity index; SLICC = systemic lupus international collaborating clinics group
damage index; BP = blood pressure.
Table 2 Cardiovascular risk factors and current corticosteroid use
Factor Corticosteroids (N = 60) No corticosteroids (N = 39) PP (Adjusted)
Systolic BP (mm Hg) 121.7  19.1 116.3  15.0 0.14 0.40
Diastolic BP (mm Hg) 75.8  14.4 70.8  12.6 0.04 0.16
HDL cholesterol (mg/dL) 48.9  16.0 46.5  12.8 0.68 0.25
LDL cholesterol (mg/dL) 108.9  43.1 100.1  25.6 0.31 0.41
Triglycerides (mg/dL) 135.1  61.4 95.3  47.5 0.001 0.003
Glucose (mg/dL) 88.6  33.1 84.9  13.1 0.70 0.67
Homocysteine (umol/L) 9.78  2.98 8.55  2.31 0.05 0.11
F2-Isoprostane (ng/mg Creatinine) 2.82  2.31 2.87  2.47 0.88 0.96
P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean  SD.
Table 3 Cardiovascular risk factors and current antimalarial use
Factor Antimalarials (N = 64) No antimalarials (N = 35) PP (Adjusted)
Systolic BP (mm Hg) 118.7  15.0 121.2  22.0 0.97 0.59
Diastolic BP (mm Hg) 73.3  12.3 74.7  16.4 0.75 0.68
HDL cholesterol (mg/dL) 48.1  13.2 47.7  17.4 0.59 0.62
LDL cholesterol (mg/dL) 108.2  39.4 100.3  33.1 0.69 0.23
Triglycerides (mg/dL) 117.1  63.2 123.6  52.2 0.25 0.52
Glucose (mg/dL) 85.3  19.3 90.4  37.3 0.46 0.46
Homocysteine(umol/L) 9.27  2.70 9.33  2.97 0.89 0.96
F2 Isoprostane (ng/mg Creatinine) 2.66  2.23 3.13  2.56 0.48 0.46
P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean  SD.
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lycerides even after adjustment for age, sex, and
diseaseactivity(SLEDAI)(P = 0.003).Antimalarial
use was not associated with altered cardiovascular
risk factors. Neither NSAIDs nor COX-2 inhibi-
tors were associated with increased blood pressure
or other risk factors. When patients taking (31
patients, 9 ACEI users) or not taking antihyperten-
sive drugs were analyzed separately, blood pressure
did not differ between non-NSAID and NSAID
users (non-antihypertensive drug users: systolic
116.4  13.4 mm Hg vs. 115.7  13.8 mm Hg,
Table 4 Cardiovascular risk factors and current NSAID use
Factor NSAIDs (N = 22) No NSAIDs (N = 77) PP (Adjusted)
Systolic BP (mm Hg) 118.8  14.8 119.8  18.5 0.87 0.85
Diastolic BP (mm Hg) 71.1  12.6 74.6  14.2 0.39 0.42
HDL cholesterol (mg/dL) 50.0  16.6 47.4  14.3 0.46 0.78
LDL cholesterol (mg/dL) 107.4  31.6 104.8  39.0 0.37 0.72
Triglycerides (mg/dL) 101.8  47.6 124.4  61.7 0.12 0.11
Glucose (mg/dL) 86.6  16.8 87.3  29.3 0.68 0.71
Homocysteine(umol/L) 9.19  2.32 9.32  2.92 0.81 0.88
F2 Isoprostane (ng/mg Creatinine) 3.10  1.94 2.75  2.49 0.13 0.23
P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean  SD.
Table 5 Cardiovascular risk factors and current COX-2 inhibitor use
Factor COX-2 (N = 11) No COX-2 (N = 88) PP (Adjusted)
Systolic BP (mm Hg) 118.7  15.3 120.0  18.1 0.97 0.72
Diastolic BP (mm Hg) 73.1  9.3 73.9  14.3 0.98 0.85
HDL cholesterol (mg/dL) 51.9  12.1 47.5  15.0 0.23 0.39
LDL cholesterol (mg/dL) 91.5  25.6 107.1  38.3 0.14 0.17
Triglycerides (mg/dL) 83.5  50.2 123.9  59.1 0.01 0.021
Glucose (mg/dL) 91.6  21.7 86.6  27.6 0.25 0.70
Homocysteine(umol/L) 8.58  2.37 9.38  2.83 0.31 0.29
F2 Isoprostane (ng/mg Creatinine) 1.36  0.71 2.98  2.41 0.06 0.03
P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean  SD.
Table 6 Cardiovascular risk factors and current azathioprine use
Factor Azathioprine (N = 10) No Azathioprine (N = 89) PP (Adjusted)
Systolic BP (mm Hg) 117.9  18.3 119.8  17.7 0.83 0.53
Diastolic BP (mm Hg) 66.7  16.1 74.6  13.4 0.16 0.034
HDL cholesterol (mg/dL) 53.9  15.0 47.3  14.7 0.15 0.09
LDL cholesterol (mg/dL) 89.3  26.2 107.2  38.0 0.09 0.09
Triglycerides (mg/dL) 98.9  39.7 121.7  60.9 0.37 0.22
Glucose (mg/dL) 84.3  11.4 87.5  28.2 0.81 0.77
Homocysteine(umol/L) 9.62  3.40 9.25  2.72 0.90 0.90
F2 Isoprostane (ng/mg Creatinine) 3.38  1.78 2.78  2.42 0.21 0.16
P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean  SD.
Table 7 Cardiovascular risk factors and current methotrexate (MTX) use
Factor MTX (N = 9) No MTX (N = 90) PP (Adjusted)
Systolic BP (mm Hg) 133.4  19.9 118.2  17.0 0.01 0.047
Diastolic BP (mm Hg) 79.7  16.1 73.2  13.5 0.16 0.33
HDL cholesterol (mg/dL) 43.2  13.9 48.4  14.8 0.28 0.46
LDL cholesterol (mg/dL) 123.2  28.2 103.6  37.8 0.06 0.23
Triglycerides (mg/dL) 161.7  56.2 115.2  58.3 0.02 0.05
Glucose (mg/dL) 88.1  12.5 87.0  28.1 0.25 0.96
Homocysteine(umol/L) 11.22  3.07 9.09  2.69 0.03 0.08
F2 Isoprostane (ng/mg Creatinine) 3.11  3.30 2.80  2.24 0.87 0.85
P = unadjusted P values; P (adjusted) = adjusted for age, sex, and SLEDAI. Data are shown as mean  SD.
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 12.5 mm Hg, P = 0.68; anti-hypertensive
users: systolic 126.5  24.8 mm Hg vs. 129.5
 14.2 mm Hg, P = 0.50; diastolic 78.6 
18.9 mm Hg vs. 71.8  14.4 mm Hg, P = 0.45).
COX-2 inhibitors were weakly associated with
lower serum triglyceride concentrations and
F2-isoprostaneexcretionafterstatisticaladjustment
(P = 0.02 and P = 0.03, Table 5). Methotrexate use
was associated with higher serum homocysteine
concentrations (unadjusted P = 0.03) but this was
attenuated after statistical adjustment (P = 0.08,
Table 7). Systolic blood pressure and triglyceride
concentrations also tended to be higher in patients
receiving methotrexate.
Discussion
The major ﬁnding of this study is that current
exposure to drugs used to treat SLE is not a major
contributor to the cardiovascular risk factors
studied.
Corticosteroids
Systemic corticosteroids increase concentrations
of triglycerides and blood pressure. Corticoster-
oids are thought to induce dyslipidemia through
increased production of HDL, impaired catabo-
lism of LDL, and increased lipoprotein lipase
activity [3]. They also induce hypertension by
increasedsystemicvascularresistance,extracellular
volume, and cardiac contractility [3]. Corticoster-
oids are also known to induce glucose intolerance
[13]. This study indicates that current corticoster-
oid use in patients with SLE is associated with
higher triglyceride concentrations, but not with
increased blood pressure or serum glucose concen-
trations. We have previously shown that cumula-
tiveexposuretocorticosteroidswasassociatedwith
higher triglyceride concentrations [14].
Antimalarials
Use of antimalarials may decrease total and LDL
cholesterol and triglyceride concentrations, and
decreases the risk of thrombosis in patients with
SLE [6,15,16]. In this study current antimalarial
use was not associated with signiﬁcant differences
in lipid concentrations or cardiovascular risk
factors. A potential explanation that should be
considered is a type II error (i.e., lack of statistical
power). However, based on previous data [6]
reporting that antimalarials decreased LDL con-
centrations by approximately 26 mg/dL, a post-
hoc power analysis using PS [17] showed that our
sample size had approximately 93% power to
detect an effect of similar magnitude. Thus, lack of
statistical power is an unlikely explanation. We
have previously reported that cumulative hydroxy-
chloroquine use was not associated with lipid con-
centrations in this cohort of patients [14].
NSAIDs and COX-2 Inhibitors
Traditional NSAIDs, and particularly COX-2
inhibitors, increase cardiovascular risk [4,5]. One
mechanism by which NSAIDs and COX-2 inhibi-
torscanincreasecardiovascularriskisbyincreasing
blood pressure. However, blood pressure did not
differamongpatientsreceivingNSAIDsorCOX-2
inhibitorsandthosewhodidnot.Triglyceridecon-
centrations were lower in patients taking COX-2
inhibitors, but when additional statistical adjust-
ment for corticosteroid use was performed, the
association was no longer signiﬁcant (P = 0.08).
There is some experimental [18,19] and clinical
evidence [20] that COX-2 inhibitors may be asso-
ciatedwithadecreaseintotalcholesterol,LDLand
triglycerideconcentrations.CurrentuseofCOX-2
inhibitorswasassociatedwithlowerF2-isoprostane
excretion, indicative of lower oxidative stress.
Other studies have suggested that COX-2 selective
drugs can decrease oxidative stress [21,22].
Methotrexate
Methotrexate is widely used to treat rheumatoid
arthritis and there are several reports indicating
that it increases serum homocysteine concentra-
tions due to folate antagonism [23,24]. Concor-
dant with those ﬁndings, this study showed an
association between current use of methotrexate
and increased serum homocysteine concentrations
that was of marginal signiﬁcance after adjustment
for sex, age and SLEDAI. Since only 9 patients
were receiving methotrexate, a larger sample
would be required to further examine this ob-
servation. The modestly statistically signiﬁcant
differences in systolic blood pressure and triglyc-
erides may be the result of the non-random design
since these do not appear to be a feature of meth-
otrexate therapy in large studies of patients with
rheumatoid arthritis [25,26].
Limitations
This study has several limitations. First, it was
cross-sectional, and the pattern of drug use may
have been affected by indication bias. Thus,
patients with hypertension, for example, would be
less likely to continue to receive drugs such as
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study provides valuable information about the
relationship between current use of drugs and car-
diovascular risk factors. For example, in this same
cohort of patients, blood pressure was signiﬁcantly
higher than that of controls [2], however the ﬁnd-
ings of the current study suggest that this is not
explained by current exposure to NSAIDs, COX-2
selective drugs, or corticosteroids. The second
limitation is that drugs would be prescribed differ-
entially according to SLE activity. We performed
statistical adjustment for current disease activity
using the SLEDAI score and therefore such bias
may be reduced. Third, since the study was explor-
atory, we have performed multiple statistical com-
parisons without statistical adjustment and should
be considered when interpreting the results. Nev-
ertheless, since randomized controlled trials to
examine the effects of the drugs of interest on
cardiovascular risk factors in SLE are not feasible,
the study provides useful information, despite its
limitations.
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